Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Chris Soria"'
Autor:
Maysoun Shomali, Zhuyan Guo, Jane Cheng, Amy Sullivan, Youssef El-Ahmad, Fangxian Sun, Sukhvinder Sidhu, Joon Sang Lee, Hui Cai, Jack Pollard, Laurent Debussche, Chris Soria, Monsif Bouaboula
Publikováno v:
Cancer Research. 82:P4-02
Nearly 70% of newly diagnosed cases of breast cancer (BC) are estrogen receptor positive (ER+) where endocrine therapy is a primary treatment. Despite initial efficacy seen with endocrine therapies, approximately 40% of patients develop acquired resi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a2505d83d780d649e8ce322533ce5307
https://doi.org/10.1158/1538-7445.sabcs21-p4-02-08
https://doi.org/10.1158/1538-7445.sabcs21-p4-02-08
Autor:
Fangxian Sun, Youssef El-Ahmed, Monsif Bouaboula, Vasiliki Pelekanou, Marina Celanovic, Laurent Debussche, Christina I. Herold, Chris Soria, Joon Sang Lee, Jack Pollard, Patrick Cohen, Maysoun Shomali, Laurent Schio, Laurent Besret, Anne Caron
Publikováno v:
Cancer Research. 81:739-739
Primary treatment for estrogen receptor-positive (ER+) breast cancer is endocrine therapy. Selective estrogen receptor degraders (SERDs), such as fulvestrant, induce effective ER signaling inhibition, although clinical studies with fulvestrant report
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e1ac31d42db3a4bdafe580b1765bf581
https://doi.org/10.1158/1538-7445.am2021-739
https://doi.org/10.1158/1538-7445.am2021-739
Autor:
Joon Sang Lee, Youssef El-Ahmad, Fangxian Sun, Mikhail Levit, Laurent Schio, Laurent Debussche, Chris Soria, Patrick Cohen, Jack Pollard, Monsif Bouaboula, Maysoun Shomali
Publikováno v:
Cancer Research. 81:PS17-16
Primary treatment for estrogen receptor-positive (ER+) breast cancer is endocrine therapy. However, substantial evidence indicates a continued role for ER signaling in tumor progression. Selective estrogen receptor degraders (SERDs), such as fulvestr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5e186a43c98094949abb92927c9ade84
https://doi.org/10.1158/1538-7445.sabcs20-ps17-16
https://doi.org/10.1158/1538-7445.sabcs20-ps17-16
Autor:
Frank Halley, Mikhail Levit, Laurent Debussche, Patrick Cohen, Dietmar Hoffman, Vicky Richon, Sylvie Vincent, Gary McCort, Monsif Bouaboula, Karl Hsu, Zhuyan Guo, Carlos Garcia-Echeverria, Fangxian Sun, Maysoun Shomali, Laurent Schio, Francisco Adrian, Hong Cheng, Chris Soria, Laurent Bestret, Natalia Malkova, Christoph Winter, Malvika Koundinya, Joanne Lager, Stephane Poirier, Hui Cao, Youssef El-Ahmad, Jane Cheng
Publikováno v:
Cancer Research. 78:943-943
Despite resistance to endocrine therapies, estrogen receptor-positive (ER+) breast cancers (BC) still rely on ER. Eliminating ER by inducing its degradation with selective ER downregulators (SERD) should induce complete ablation of ER pathways. The c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a7a22c0362253bb125a6d7e4c17b0333
https://doi.org/10.1158/1538-7445.am2018-943
https://doi.org/10.1158/1538-7445.am2018-943